

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Previously Presented):** A bispecific single chain antibody construct, whereby said bispecific single chain antibody construct comprises at least two domains,
 - (a) wherein a first domain of said at least two domains specifically binds to-the human CD3 complex, wherein said first domain comprises an amino acid sequence of an antibody light chain having the amino acid sequence selected from the group consisting of:
 - (i) the amino acid sequence of SEQ ID NO.: 10;
 - (ii) the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO.: 9; and
 - (iii) the amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of (ii); and
 - (b) wherein a second domain is or contains at least one antigen-binding-site and/or at least one effector domain.
- 2-3. **(Canceled)**
4. **(Previously Presented):** The bispecific single chain antibody construct according to claim 1, wherein the first domain which binds to-the human CD3 complex is a scFv.
5. **(Canceled)**
6. **(Previously Presented):** The bispecific single chain antibody construct according to claim 1, wherein the first domain which binds to-the human CD3 complex comprises or consists of the amino acid sequence as depicted in SEQ ID NO.: 14 or encoded by the nucleic acid sequence of SEQ ID NO: 13.

7. **(Previously Presented):** The bispecific single chain antibody construct according to claim 1, wherein said antigen-binding-site in said second domain is specific for one or more cell surface molecule(s).

8. **(Previously Presented):** The bispecific single chain antibody construct according to claim 7, wherein said one or more cell surface molecule(s) is/are a tumor specific molecule(s).

9. **(Previously Presented):** The bispecific single chain antibody construct according to claim 7, wherein said second domain is a scFv.

10. **(Previously Presented):** The bispecific single chain antibody construct according to claim 7, wherein said second domain specifically binds to-an antigen selected from the group consisting of EpCAM, CCR5, CD19, HER-2, HER-3, HER-4, EGFR, PSMA, CEA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, bhCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3, 9-O-Acetyl-GD3, GM2, Globo H, fucosyl GM1, Poly SA, GD2, Carboanhydrase IX (MN/CA IX), CD44v6, Sonic Hedgehog (Shh), Wue-1, Plasma Cell Antigen, (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), CCR8, TNF-alpha precursor, STEAP, mesothelin, A33 Antigen, Prostate Stem Cell Antigen (PSCA), Ly-6 desmoglein 4, E-cadherin neoepitope, Fetal Acetylcholine Receptor, CD25, CA19-9 marker, CA-125 marker and Muellerian Inhibitory Substance (MIS) Receptor type II, sTn (sialylated Tn antigen; TAG-72), FAP (fibroblast activation antigen), endosialin, EGFRvIII, L6, SAS, CD63, TF-antigen, Cora antigen, CD7, CD22, Ig α , Ig β , gp100, MT-MMPs, F19-antigen and CO-29.

11. **(Withdrawn and Currently Amended):** The bispecific single chain antibody construct according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of SEQ ID NO.: 16 or 18;
- (b) an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO.: 15 or 17; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of any of (b).

12. (Withdrawn): The bispecific single chain antibody construct according to claim 11, wherein said single chain antibody construct comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of SEQ ID NO.: 20;
- (b) an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO.: 21; and
- (c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of (b).

13. (Previously Presented): The bispecific single chain antibody construct according to claim 10, wherein said second domain comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of SEQ ID NO.: 22, 24, 26, 28, 30 or 32;
- (b) an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO.: 21, 23, 25, 27, 29 or 31; and
- (c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of any one of (b).

14. (Previously Presented): The bispecific single chain antibody construct according to claim 13, wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group consisting of:

- (a) an amino acid sequence of SEQ ID NO.: 34 or 36;
- (b) an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO.: 33 or 35; and
- (c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to the nucleic acid sequence of any one of (b).

15. (Previously Presented): The bispecific single chain antibody construct according to claim 7, wherein said antigen-binding site is humanized.

16. (Withdrawn - Currently Amended): ~~[[A]]~~ An isolated nucleic acid ~~sequence~~ encoding the bispecific single chain antibody construct according to claim 1.

17. (Withdrawn - Currently Amended): The nucleic acid ~~sequence~~ of claim 16 comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding the mature form of a protein comprising the amino acid sequence selected from the group of SEQ ID NOs: 20, 34 and 36;

(b) a nucleotide sequence comprising or consisting of a DNA sequence selected from the group of SEQ ID NOs: 19, 33 and 35;

~~(c) a nucleotide sequence encoding a protein having an amino acid sequence at least 95% identical to the amino acid sequence encoded by the nucleotide sequence of (a) or (b); and~~

~~(d)~~(c) a nucleotide sequence which is degenerate as a result of the genetic code to a nucleotide sequence of any one of (a) or (b) ~~to (c)~~.

18. (Withdrawn - Currently Amended): ~~[[A]]~~ An isolated vector comprising the nucleic acid ~~sequence~~ according to claim 16.

19. (Withdrawn - Currently Amended): The isolated vector of claim 18, which further comprises a regulatory sequence operably linked to said nucleic acid ~~sequence~~.

20. (Withdrawn - Currently Amended): The isolated vector of claim 18, wherein the vector is an expression vector.

21. (Withdrawn - Currently Amended): ~~[[A]]~~ An isolated host transformed or transfected with the nucleic acid of claim 16 or a vector comprising the nucleic acid ~~according to claim 18.~~

22. (Withdrawn - Currently Amended): A process for the production of a bispecific single chain antibody construct according to claim 1, said process comprising culturing ~~[[a]]~~ an isolated host transformed or transfected with the nucleic acid of claim 16 or a vector comprising ~~[[a]]~~ the nucleic acid sequence encoding the bispecific single chain antibody construct of claim 1 under conditions allowing the expression of the bispecific

single chain antibody construct and recovering the produced bispecific single chain antibody construct from the culture.

23. (Previously Presented): A composition comprising the bispecific single chain antibody construct according to claim 1 and, optionally, a proteinaceous compound capable of providing an activation signal for immune effector cells.

24. (Original): The composition of claim 23 which is a pharmaceutical composition further comprising suitable formulations of carrier, stabilizers and/or excipients.

25. (Previously Presented): The composition of claim 23 which is a diagnostic composition for detection of proliferative diseases, tumorous diseases, inflammatory diseases, immunological disorders, autoimmune diseases, infectious diseases, viral diseases, allergic reactions, parasitic reactions, graft-versus-host diseases or host-versus-graft diseases.

26. - 30. (Canceled)

31. (Previously Presented): A kit comprising the bispecific single chain antibody construct according to claim 1.